Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma

You may also be interested in...



Korea’s Celltrion Will Support Hospira On EU Infliximab Sales While Setting Sights On Japan

How Celltrion and Hospira will share the European market remains to be seen, but Celltrion says the partners will support each other in taking on J&J’s Remicade. The Korean company also files for approval of infliximab in Japan, setting up another potential battleground on biosimilars.

As Speculation Mounts In Korea, Biosimilar Play Celltrion Still Seems Likely To Sell To Big Pharma

Although Celltrion has raised eyebrows by saying it would consider the best interests of Korea’s pharmaceutical industry in a potential sale, most analysts still believe a multinational will win out. Speculation has heated up after a local report singled out AstraZeneca as a potential suitor.

Celltrion Files For Korea Approval Of Herceptin Biosimilar

Amid M&A talks and expectations for imminent European approval of a Remicade biosimilar, Celltrion becomes the first company to file for regulatory approval of a biosimilar of Roche’s blockbuster breast cancer therapy trastuzumab.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC076388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel